Xiao Yu, Heck Vincent, Hao Long, Rauschmann Michael, Slavici Andrei
Center for Spinal Surgery, Sana Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Germany.
Department of Spinal Surgery, Fourth People's Hospital of Guiyang, Guiyang, China.
Orthopadie (Heidelb). 2025 May 13. doi: 10.1007/s00132-025-04657-0.
To evaluate the efficacy of intraoperative gentamicin versus vancomycin-loaded PerOssal (Osartis, Münster, Germany) carriers on interbody fusion rates and infection control in patients undergoing surgery for pyogenic spondylodiscitis.
This retrospective study included 29 patients with pyogenic spondylodiscitis who underwent surgical debridement, interbody fusion, and pedicle screw fixation between February 2018 and March 2023. Patients received PerOssal carriers loaded with either gentamicin (Group A, n = 14) or vancomycin (Group B, n = 15). Clinical outcomes, including fusion rates, infection control, complications, and inflammatory markers, were analyzed.
Baseline characteristics between groups were comparable. Fusion rates at 3-6 months' follow-up were 92.8% (13/14) in Group A and 80.0% (12/15) in Group B, without significant differences (P > 0.05). Both groups showed significant reductions in white blood cell counts and C‑reactive protein levels postoperatively, without inter-group differences (P > 0.05). Complications included cerebrospinal fluid leakage, hematoma, pulmonary embolism, and wound infections, all managed successfully with no recurrent infections observed.
In the short term, PerOssal carriers loaded with either gentamicin or vancomycin demonstrated effective infection control for pyogenic spondylodiscitis and high interbody fusion rates. Moreover, no apparent adverse effects on bone healing were associated with the local administration of high-concentration antibiotics.
评估术中使用庆大霉素与载有万古霉素的PerOssal(德国明斯特的Osartis公司生产)载体对化脓性脊椎间盘炎手术患者椎间融合率和感染控制的疗效。
这项回顾性研究纳入了29例在2018年2月至2023年3月期间接受手术清创、椎间融合和椎弓根螺钉固定的化脓性脊椎间盘炎患者。患者接受载有庆大霉素的PerOssal载体(A组,n = 14)或载有万古霉素的PerOssal载体(B组,n = 15)。分析临床结果,包括融合率、感染控制、并发症和炎症标志物。
两组间的基线特征具有可比性。A组在3至6个月随访时的融合率为92.8%(13/14),B组为80.0%(12/15),无显著差异(P>0.05)。两组术后白细胞计数和C反应蛋白水平均显著降低,组间无差异(P>0.05)。并发症包括脑脊液漏、血肿、肺栓塞和伤口感染,所有并发症均成功处理,未观察到复发性感染。
短期内,载有庆大霉素或万古霉素的PerOssal载体对化脓性脊椎间盘炎显示出有效的感染控制和较高的椎间融合率。此外,局部应用高浓度抗生素对骨愈合无明显不良影响。